Recent clinical studies have suggested that phenylacetylglutamine (PAGln), a novel gut microbial metabolite, can mechanistically modulate patients' risk of developing cardiovascular disease (CVD) and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback